Charles River Laboratories International (CRL) Debt to Equity (2009 - 2025)

Charles River Laboratories International's Debt to Equity history runs 17 years deep, the most recent figure standing at $0.67 for Q4 2025.

• In Q4 2025, Debt to Equity rose 4.14% year-over-year to $0.67; the TTM figure through Dec 2025 stood at $0.67 (up 4.14% YoY), while the FY2025 annual figure was $0.67, up 4.14% from the prior year.
• Debt to Equity was $0.67 for Q4 2025 at Charles River Laboratories International, up from $0.64 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $1.19 in Q3 2021 to a low of $0.61 in Q3 2024.
• Historically, Debt to Equity has averaged $0.86 across 5 years, with a median of $0.8 in 2025.
• The sharpest annual moves came in 2021 and 2023: Debt to Equity climbed 12.36% in 2021, then slumped 31.98% in 2023.
• A 5-year view of Debt to Equity shows it stood at $1.05 in 2021, then decreased by 13.51% to $0.91 in 2022, then declined by 19.09% to $0.73 in 2023, then dropped by 11.93% to $0.65 in 2024, then gained by 4.14% to $0.67 in 2025.
• The last three Debt to Equity figures came in at $0.67 (Q4 2025), $0.64 (Q3 2025), and $0.69 (Q2 2025), per Business Quant data.